Table 2.
Factors associated with response to chemotherapy during follow-up of IL-2 treated patients
| N | Overall response rate (%) | P value | |
|---|---|---|---|
| All patients | 30 | 36.7 | |
| M-Substage (start of chemotherapy) | |||
| M1a | 5 | 40.0 | 0.600 |
| M1b | 8 | 50.0 | |
| M1c | 17 | 29.4 | |
| Regimen | |||
| Temozolomide/dacarbazine | 23 | 47.8 | 0.021 |
| Polychemotherapy/other | 7 | 0.0 | |
| Stage (start IL-2 treatment) | |||
| III | 20 | 40.0 | 0.592 |
| IV | 10 | 30.0 | |
| Dosage IL-2 | |||
| ≥60 MIU | 18 | 55.6 | 0.009 |
| <60 MIU | 12 | 8.3 | |
| Prior chemotherapy | |||
| No | 18 | 44.4 | 0.279 |
| Yes | 12 | 25.0 | |
| Interval IL-2—chemotherapy | |||
| <12 Months | 16 | 50.0 | 0.105 |
| ≥12 Months | 14 | 21.4 | |
MIU Million Injection Units